UA115455C2 - Спосіб одержання сполук для застосування при лікуванні раку - Google Patents

Спосіб одержання сполук для застосування при лікуванні раку

Info

Publication number
UA115455C2
UA115455C2 UAA201504532A UAA201504532A UA115455C2 UA 115455 C2 UA115455 C2 UA 115455C2 UA A201504532 A UAA201504532 A UA A201504532A UA A201504532 A UAA201504532 A UA A201504532A UA 115455 C2 UA115455 C2 UA 115455C2
Authority
UA
Ukraine
Prior art keywords
cancer treatment
preparing compounds
compound
formula
mek
Prior art date
Application number
UAA201504532A
Other languages
English (en)
Ukrainian (uk)
Inventor
Срірам Наганатхан
Натхан Гуз
Меттью Пфайффер
К. Грегорі Сауелл
Трейсі Бостік
Джейсон Ян
Аміт Срівастава
Original Assignee
Екселіксіс, Інк.
Дженентек, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Екселіксіс, Інк., Дженентек, Інк. filed Critical Екселіксіс, Інк.
Publication of UA115455C2 publication Critical patent/UA115455C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
UAA201504532A 2012-10-12 2013-10-14 Спосіб одержання сполук для застосування при лікуванні раку UA115455C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713104P 2012-10-12 2012-10-12
PCT/US2013/064866 WO2014059422A1 (en) 2012-10-12 2013-10-14 Novel process for making compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
UA115455C2 true UA115455C2 (uk) 2017-11-10

Family

ID=49474740

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201504532A UA115455C2 (uk) 2012-10-12 2013-10-14 Спосіб одержання сполук для застосування при лікуванні раку

Country Status (31)

Country Link
US (4) US9771347B2 (enExample)
EP (1) EP2909188B1 (enExample)
JP (2) JP6300042B2 (enExample)
KR (1) KR102204520B1 (enExample)
CN (2) CN108948043B (enExample)
AU (1) AU2013328929B2 (enExample)
BR (1) BR112015008113B1 (enExample)
CA (1) CA2889466C (enExample)
CL (1) CL2015000926A1 (enExample)
CR (2) CR20200237A (enExample)
EA (1) EA030613B1 (enExample)
ES (1) ES2671502T3 (enExample)
GE (1) GEP201706690B (enExample)
HK (1) HK1213567A1 (enExample)
HR (1) HRP20180670T1 (enExample)
IL (1) IL238116B (enExample)
IN (1) IN2015DN03928A (enExample)
MA (1) MA38085B1 (enExample)
MX (2) MX372708B (enExample)
MY (1) MY186549A (enExample)
NZ (1) NZ706723A (enExample)
PE (3) PE20191818A1 (enExample)
PH (1) PH12015500785B1 (enExample)
PL (1) PL2909188T3 (enExample)
SA (1) SA515360271B1 (enExample)
SG (1) SG11201502795VA (enExample)
SI (1) SI2909188T1 (enExample)
TR (1) TR201807861T4 (enExample)
UA (1) UA115455C2 (enExample)
WO (1) WO2014059422A1 (enExample)
ZA (1) ZA201502349B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201502795VA (en) 2012-10-12 2015-05-28 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona
JP6914202B2 (ja) 2015-06-30 2021-08-04 ジェネンテック, インコーポレイテッド 薬物を含有する即放性錠剤及び錠剤の形成プロセス
CN105330643B (zh) * 2015-12-09 2017-12-05 苏州明锐医药科技有限公司 卡比替尼的制备方法
CN106045969B (zh) * 2016-05-27 2019-04-12 湖南欧亚药业有限公司 一种卡比替尼的合成方法
AU2017311585A1 (en) 2016-08-12 2019-02-28 Genentech, Inc. Combination therapy with a MEK inhibitor, a PD-1 axis inhibitor, and a VEGF inhibitor
CN109862917A (zh) 2016-09-29 2019-06-07 基因泰克公司 Mek抑制剂,pd-1轴抑制剂,和紫杉烷的组合疗法
WO2020187674A1 (en) 2019-03-15 2020-09-24 Sandoz Ag Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate
JP2024509269A (ja) 2021-03-09 2024-02-29 ジェネンテック, インコーポレイテッド 脳がんの治療における使用のためのベルバラフェニブ
JP2024514112A (ja) 2021-04-06 2024-03-28 ジェネンテック, インコーポレイテッド ベルバラフェニブおよびコビメチニブを用いた併用療法、またはベルバラフェニブ、コビメチニブおよびアテゾリズマブを用いた併用療法

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1563587A (en) * 1924-09-20 1925-12-01 Raney Murray Method of preparing catalytic material
US1628190A (en) * 1926-05-14 1927-05-10 Raney Murray Method of producing finely-divided nickel
US1915473A (en) * 1930-12-31 1933-06-27 Raney Murray Method of preparing catalytic material
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
CA2186947A1 (en) 1994-04-01 1995-10-12 Kazuo Ueda Oxime derivative and bactericide containing the same as active ingredients
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1998037881A1 (en) 1997-02-28 1998-09-03 Warner Lambert Company Method of treating or preventing septic shock by administering a mek inhibitor
ES2274572T3 (es) 1997-07-01 2007-05-16 Warner-Lambert Company Llc Derivados de acido 2-(4-bromo- o 4-yodo-fenilamino) benzoico y su uso como inhibidor de mek.
HUP0003731A3 (en) 1997-07-01 2002-11-28 Warner Lambert Co 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
US6310060B1 (en) * 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
US6974878B2 (en) 2001-03-21 2005-12-13 Symyx Technologies, Inc. Catalyst ligands, catalytic metal complexes and processes using same
IL143231A0 (en) 1998-12-15 2002-04-21 Warner Lambert Co Use of a mek inhibitors for preventing transplant rejection
AU776788C (en) 1998-12-16 2005-10-27 Warner-Lambert Company Treatment of arthritis with MEK inhibitors
ES2253928T3 (es) 1998-12-22 2006-06-01 Warner-Lambert Company Llc Quimioterapia de combinacion que comprende un inhibidor mitotico y un inhibidor mek.
KR20000047461A (ko) 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
WO2000040237A1 (en) 1999-01-07 2000-07-13 Warner-Lambert Company Antiviral method using mek inhibitors
EP1140062B1 (en) 1999-01-07 2005-04-06 Warner-Lambert Company LLC Treatment of asthma with mek inhibitors
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
ATE302193T1 (de) 1999-01-13 2005-09-15 Warner Lambert Co Benzoheterozyklen und ihre verwendung als mek inhibitoren
CA2348236A1 (en) 1999-01-13 2000-07-20 Stephen Douglas Barrett 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors
JP2002534446A (ja) 1999-01-13 2002-10-15 ワーナー−ランバート・カンパニー 4′ヘテロアリールジアリールアミン
PL348870A1 (en) 1999-01-13 2002-06-17 Warner Lambert Co 1-heterocycle substituted diarylamines
IL147619A0 (en) 1999-07-16 2002-08-14 Warner Lambert Co Method for treating chronic pain using mek inhibitors
HK1047895A1 (zh) 1999-07-16 2003-03-14 沃尼尔‧朗伯公司 使用mek抑制剂治疗慢性疼痛的方法
KR20020015376A (ko) 1999-07-16 2002-02-27 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Mek 억제제를 사용한 만성 통증의 치료 방법
JP2003504399A (ja) 1999-07-16 2003-02-04 ワーナー−ランバート・カンパニー Mek阻害剤を用いる慢性疼痛の治療方法
JP4744050B2 (ja) 1999-09-17 2011-08-10 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ベンズアミドおよび関連するXa因子阻害剤
MXPA02008103A (es) 2000-03-15 2002-11-29 Warner Lambert Co Diarilaminas sustituidas con 5-amida como inhibidores mek.
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
SI1301472T1 (sl) 2000-07-19 2014-05-30 Warner-Lambert Company Llc Oksigenirani estri 4-jodo fenilamino benzihidroksamskih kislin
CN1458921A (zh) * 2000-08-25 2003-11-26 沃尼尔·朗伯有限责任公司 N-芳基邻氨基苯甲酸和它们的衍生物的制备方法
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
NZ518726A (en) 2001-05-09 2004-06-25 Warner Lambert Co Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor
US20040039208A1 (en) * 2001-07-20 2004-02-26 Chen Michael Huai Gu Process for making n-aryl-anthranilic acids and their derivatives
DE10141266A1 (de) 2001-08-21 2003-03-06 Syntec Ges Fuer Chemie Und Tec Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden
US7085492B2 (en) 2001-08-27 2006-08-01 Ibsen Photonics A/S Wavelength division multiplexed device
JP2005507411A (ja) 2001-10-31 2005-03-17 ファイザー・プロダクツ・インク 下肢静止不能症候群の治療における、ニコチン性アセチルコリン受容体アゴニスト。
DOP2003000556A (es) 2002-01-23 2003-10-31 Warner Lambert Co Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico.
BR0307060A (pt) 2002-01-23 2004-10-26 Warner Lambert Co ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
AR038972A1 (es) 2002-03-13 2005-02-02 Array Biopharma Inc Derivados de bencimidazol n3 alquilado como inhibidores de mek
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
DE60330227D1 (de) 2002-03-13 2010-01-07 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek-hemmer
WO2003103590A2 (en) 2002-06-11 2003-12-18 Merck & Co., Inc. (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
WO2004004644A2 (en) 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
AU2004218463B2 (en) 2003-03-03 2009-07-16 Array Biopharma, Inc. p38 inhibitors and methods of use thereof
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
JP2005162727A (ja) 2003-03-18 2005-06-23 Sankyo Co Ltd スルファミド誘導体及びその医薬組成物
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
EA010297B1 (ru) 2003-06-20 2008-08-29 ЮСиБи ФАРМА С.А. Производные тиенопиридона как ингибиторы киназ
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
US20050049276A1 (en) 2003-07-23 2005-03-03 Warner-Lambert Company, Llc Imidazopyridines and triazolopyridines
EP1651214B1 (en) 2003-07-24 2009-09-16 Warner-Lambert Company LLC Benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
JP4931419B2 (ja) 2003-09-19 2012-05-16 中外製薬株式会社 新規4−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
ZA200604580B (en) 2003-11-19 2009-08-26 Array Biopharma Inc Heterocyclic inhibitors of Mek and methods of use thereof
JP4527729B2 (ja) 2003-12-08 2010-08-18 エフ.ホフマン−ラ ロシュ アーゲー 新規チアゾール誘導体
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
PL1802579T3 (pl) * 2004-10-20 2014-04-30 Merck Serono Sa Pochodne 3-aryloaminopirydynowe
WO2006061712A2 (en) 2004-12-10 2006-06-15 Pfizer Inc. Use of mek inhibitors in treating abnormal cell growth
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
SI1934174T1 (sl) * 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
US20100075947A1 (en) 2006-08-16 2010-03-25 Exelixis, Inc. Methods of Using PI3K and MEK Modulators
TR201900306T4 (tr) 2006-12-14 2019-02-21 Exelixis Inc Mek inhibitörlerini kullanma yöntemleri.
SG11201502795VA (en) 2012-10-12 2015-05-28 Exelixis Inc Novel process for making compounds for use in the treatment of cancer
CN105992755B (zh) 2014-02-07 2018-07-13 住友化学株式会社 (r)-1,1,3-三甲基-4-氨基茚满的制造方法
AR105483A1 (es) 2015-06-30 2017-10-11 Exelixis Inc Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona

Also Published As

Publication number Publication date
CN104837826A (zh) 2015-08-12
TR201807861T4 (tr) 2018-06-21
HK1213567A1 (zh) 2016-07-08
PE20151494A1 (es) 2015-11-06
EA201590700A1 (ru) 2015-09-30
US10793541B2 (en) 2020-10-06
PE20200387A1 (es) 2020-02-24
GEP201706690B (en) 2017-06-26
MX372708B (es) 2020-05-29
AU2013328929B2 (en) 2018-01-04
CN108948043A (zh) 2018-12-07
JP2018052973A (ja) 2018-04-05
US11414396B2 (en) 2022-08-16
US9771347B2 (en) 2017-09-26
ES2671502T3 (es) 2018-06-06
WO2014059422A1 (en) 2014-04-17
MY186549A (en) 2021-07-26
PE20191818A1 (es) 2019-12-27
KR20150067339A (ko) 2015-06-17
MX2020005533A (es) 2020-10-12
AU2013328929A1 (en) 2015-04-30
PH12015500785A1 (en) 2015-06-15
CA2889466A1 (en) 2014-04-17
SA515360271B1 (ar) 2016-05-19
EA030613B1 (ru) 2018-08-31
MX2015004660A (es) 2015-08-07
CA2889466C (en) 2021-09-14
HK1213878A1 (en) 2016-07-15
IN2015DN03928A (enExample) 2015-10-02
KR102204520B1 (ko) 2021-01-20
EP2909188A1 (en) 2015-08-26
CR20200237A (es) 2020-07-26
CL2015000926A1 (es) 2015-08-28
ZA201502349B (en) 2019-12-18
US20170349569A1 (en) 2017-12-07
MA38085B1 (fr) 2018-11-30
US20190185447A1 (en) 2019-06-20
IL238116B (en) 2018-06-28
EP2909188B1 (en) 2018-03-07
US20150210668A1 (en) 2015-07-30
JP2015533175A (ja) 2015-11-19
CR20150245A (es) 2015-11-19
NZ706723A (en) 2018-07-27
BR112015008113A2 (pt) 2017-07-04
US10239858B2 (en) 2019-03-26
CN104837826B (zh) 2018-07-27
PH12015500785B1 (en) 2015-06-15
JP6300042B2 (ja) 2018-03-28
SG11201502795VA (en) 2015-05-28
MA38085A1 (fr) 2018-08-31
BR112015008113B1 (pt) 2022-05-24
US20200392104A1 (en) 2020-12-17
CN108948043B (zh) 2021-05-04
PL2909188T3 (pl) 2018-08-31
SI2909188T1 (en) 2018-07-31
HRP20180670T1 (hr) 2018-07-13

Similar Documents

Publication Publication Date Title
UA115455C2 (uk) Спосіб одержання сполук для застосування при лікуванні раку
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
EA201270752A1 (ru) Ингибиторы киназы и способ лечения злокачественной опухоли с их помощью
UA115176C2 (uk) Інгібітори протеїнкінази
PH12016500225B1 (en) Novel quinoline-substituted compound
TN2014000093A1 (en) Method of treating gastrointestinal stromal tumors
MX2016013600A (es) Método para tratar adenocarcinoma de pulmón.
EA201491149A1 (ru) Пиразолопиридиновые производные, способы их получения и их терапевтическое применение
NZ736970A (en) Process methods for phosphatidylinositol 3-kinase inhibitors
EA201590561A1 (ru) Пролекарства аминохиназолинового ингибитора киназы
NZ719444A (en) Novel dgat2 inhibitors
SG10201900564WA (en) Methods for treating cancer
UA114937C2 (uk) Спосіб стимулювання росту рослин із застосуванням карбоксамідних похідних
PH12015500867B1 (en) Treatment of prostate cancer with tor kinase inhibitors
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
MX2016004967A (es) Tratamiento para cancer pancreatico.
MX343968B (es) Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus.
EA201270237A1 (ru) Способ получения 1-бензил-3-гидроксиметил-1н-индазола и его производных и необходимые промежуточные соединения, содержащие магний
EA201590656A1 (ru) Азаиндолины
EA201490725A1 (ru) Способ лечения мукоэпидермоидной карциномы
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
PL418655A1 (pl) Kwas 3,7,11,15-tetrametylo-3-winyloheksadekanowy oraz sposób otrzymywania kwasu 3,7,11,15-tetrametylo-3-winyloheksadekanowego